How Long Does a Mitral Valve Repair Last?
For isolated posterior leaflet degenerative mitral regurgitation, mitral valve repair provides approximately 95% freedom from reoperation and >80% freedom from recurrent moderate-to-severe regurgitation at 15-20 years after surgery. 1
Durability Based on Repair Complexity
Simple Repairs (Posterior Leaflet Only)
When mitral valve repair is limited to the posterior leaflet with annuloplasty—the most standardized and straightforward repair—the outcomes are exceptional:
- 95% freedom from reoperation at 15-20 years 1
- >80% freedom from recurrent moderate or severe MR at 15-20 years 1
- Long-term survival equivalent to age-matched general population 2
- Operative mortality <1% 2
This represents the gold standard for mitral valve repair durability and should be the benchmark expectation when referring patients for surgery.
Complex Repairs (Anterior Leaflet or Both Leaflets)
When repair involves the anterior leaflet or both leaflets, durability decreases but still exceeds replacement outcomes:
- Approximately 80% freedom from reoperation at 15-20 years 2
- 60% freedom from recurrent moderate or severe MR at 15-20 years 2
Research data supports these guideline figures, with one study showing reoperation rates at 10 years improved from 24% to 10% for anterior leaflet repairs between the 1980s and 1990s, demonstrating ongoing technical refinement 3.
Rheumatic Disease
Rheumatic mitral valve disease has significantly worse durability:
- 50-60% freedom from reoperation at 20 years, even in experienced hands 1
- Limited by thickened/calcified leaflets, subvalvular disease with chordal fusion, and disease progression 1
Critical Factors Affecting Durability
Surgeon and institutional experience dramatically impacts outcomes. The guidelines emphasize that repair success correlates directly with surgical volume:
- Surgeons performing >50 mitral operations annually achieve repair rates >70% 4
- Institutions performing >25 repairs annually show improved 1-year survival and decreased reoperation risk 4
- High-volume hospitals (>140 mitral operations/year) demonstrate 77% repair rates versus 48% at low-volume centers (<36 operations/year) 2
The type of pathology matters immensely. Degenerative disease limited to the posterior leaflet represents the ideal scenario, while anterior leaflet involvement, bileaflet disease, and rheumatic etiology progressively worsen long-term durability.
Comparison to Valve Replacement
Mitral valve repair consistently outperforms replacement in long-term survival, with the survival advantage increasing over time:
- 0-5 years: 0.7% better survival with repair
- 5-10 years: 4.9% better survival with repair
- 10-15 years: 21.3% better survival with repair 5
Importantly, reoperation rates are similar between repair and replacement overall (20% vs 23% at 19 years), but repair avoids prosthesis-related complications like thromboembolism, anticoagulation hemorrhage, and structural valve deterioration 3.
Common Pitfalls to Avoid
Do not delay surgery until severe LV dysfunction develops. The guidelines specify intervention before LVEF drops below 60% or LV end-systolic dimension exceeds 40mm 2. Waiting beyond these thresholds compromises postoperative outcomes even if repair is technically successful.
Do not assume all repairs are equal. A poorly executed repair is worse than replacement 2. When surgical expertise is uncertain or anatomy is unfavorable, replacement may be the safer choice. The guideline states explicitly: "When in doubt, MVR is preferable to a poor repair" 2.
Do not overlook the importance of residual MR. Even mild residual MR immediately post-repair predicts worse long-term outcomes. The expectation should be no or trivial residual MR in >90% of posterior leaflet repairs 2.
Bottom Line for Clinical Practice
For the typical patient with degenerative posterior leaflet disease undergoing repair at an experienced center, expect the repair to last 15-20 years with >80% remaining free of significant recurrent regurgitation. More complex repairs involving anterior leaflet pathology still provide good durability (60-80% at 15-20 years) that exceeds replacement outcomes. Rheumatic disease has substantially worse durability (50-60% at 20 years) and should prompt careful patient selection.